| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/18/2010 | WO2009120697A3 Method and compositions for treatment of cancer |
| 02/18/2010 | WO2009114826A3 Treatment systems and methods for renal-related diseases |
| 02/18/2010 | WO2009112488A4 Polyether polyol dendron conjugates with effector molecules for biological targeting |
| 02/18/2010 | WO2008109825A3 Inducing immune-mediated tumor cell death |
| 02/18/2010 | US20100041827 Multilayer binding; lamellar surface structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure; organized mobile multifunctional conjugate (OMMC) assembly |
| 02/18/2010 | US20100041826 Multilayer binding; lamellar surface structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure; organized mobile multifunctional conjugate (OMMC) assembly |
| 02/18/2010 | US20100041749 Organo-Arsenoxide Compounds and Use Thereof |
| 02/18/2010 | US20100041747 Use of certain chemical compounds for the inhibition of the peptidyl-prolyl cis/trans isomerase activity of cyclophilins |
| 02/18/2010 | US20100041745 Aigialomycin D and Derivatives Thereof and Their Use in Treating Cancer or Malaria or a Microbial Infection |
| 02/18/2010 | US20100041744 Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof |
| 02/18/2010 | US20100041726 INHIBITORS OF Akt ACTIVITY |
| 02/18/2010 | US20100041721 Selective androgen receptor modulators |
| 02/18/2010 | US20100041719 Mitotic kinesin inhibitors and methods of use thereof |
| 02/18/2010 | US20100041708 N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for it's preparation |
| 02/18/2010 | US20100041692 Pyrrolo[4,3,2-de]quinolin-8-amine compounds and methods of their preparation and use |
| 02/18/2010 | US20100041685 Stat3 inhibitors |
| 02/18/2010 | US20100041681 2-amino pyrimidine compounds as potent hsp-90 inhibitors |
| 02/18/2010 | US20100041666 Use of N-Phenyl-2-pyrimidineamine Derivativea Against Mast Cell-based Diseases Like Allergic Disorders |
| 02/18/2010 | US20100041663 Organic Compounds as Smo Inhibitors |
| 02/18/2010 | US20100041645 Rho kinase inhibitors |
| 02/18/2010 | US20100041636 Novel kinase inhibitors |
| 02/18/2010 | US20100041635 Oxindole compounds |
| 02/18/2010 | US20100041628 Novel indole derivative having ikappab kinase beta inhibitory activity |
| 02/18/2010 | US20100041625 Pharmaceutical composition comprising cyclodextrin paclitaxel inclusion and preparation method thereof |
| 02/18/2010 | US20100041619 Lasonolide compounds as reagents for inducing premature chromosome condensation and methods for treating disorders |
| 02/18/2010 | US20100041617 Modulating mxa expression |
| 02/18/2010 | US20100041598 Use of Prolactin in the Prophylactic Treatment of Cancer |
| 02/18/2010 | US20100041594 Use of Aplidine for the Treatment of Pancreatic Cancer |
| 02/18/2010 | US20100041592 Use of Amphiphilic Biocompatible Polymers for Solubilization of Hydrophobic Drugs |
| 02/18/2010 | US20100041136 Connective Tissue Growth Factor-2 |
| 02/18/2010 | US20100041072 Process for identifying a ligand that binds to the nep binding site for the smr1 pentapeptide |
| 02/18/2010 | US20100041028 Zinc finger binding domains for GNN |
| 02/18/2010 | US20100040645 In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete domain and is cd4+ t cell-independent |
| 02/18/2010 | US20100040637 Methods and Composition for Treating Diseases Targeting Prominin-1 (CD133) |
| 02/18/2010 | US20100040636 Manipulation of Regulatory T Cell and Dc Function By Targeting Neuritin Gene Using Antibodies, Agonists and Antagonists |
| 02/18/2010 | US20100040634 Methods and compositions for modulating hgf/met |
| 02/18/2010 | US20100040629 Antibodies to c-Met |
| 02/18/2010 | US20100040628 Indoprofen derivatives for promoting bone growth |
| 02/18/2010 | US20100040622 Netrin-related compositions and uses |
| 02/18/2010 | US20100040613 Polypeptide constructs for sublingual administration |
| 02/18/2010 | US20100040611 Antagonists of pcsk9 |
| 02/18/2010 | US20100040610 Antagonists of pcsk9 |
| 02/18/2010 | US20100040604 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha |
| 02/18/2010 | US20100040603 Methods for promoting protection and regeneration of bone marrow using cxcl9 and anti-cxcl9 antibodies |
| 02/18/2010 | US20100040578 Malignant Tumor Cell Suppressor Protein, Malignant Tumor Cell Suppressor Gene, Maligant Tumor Cell Suppressive Viral Vector, and Kit Using the Same |
| 02/18/2010 | US20100040574 TREATMENT OF CANCER WITH ANTI-IL-1alpha ANTIBODIES |
| 02/18/2010 | US20100040555 Magnetic Nanoparticles Compositions and Uses Thereof |
| 02/18/2010 | US20100040550 Radiolabelling methods |
| 02/18/2010 | US20100040542 Chelator conjugates |
| 02/18/2010 | US20100040539 Vector System |
| 02/18/2010 | US20100040537 antibodies that are wild-type, chimeric, CDR grafted and humanized; disease or disorder in which prostaglandin E2 activity is detrimental, such as cancer, atuoimmune diseases, inflammatory diseases |
| 02/18/2010 | DE102008039417A1 Mittel zum Nachweis und zur Behandlung von Prostatazellen Means for the detection and treatment of prostate cells |
| 02/18/2010 | CA2737219A1 Halofuginone analogs for inhibition of trna synthetases and uses thereof |
| 02/18/2010 | CA2735562A1 Organic compounds for wound healing |
| 02/18/2010 | CA2734389A1 S0x9, prostaglandin d2 and retinoic acid for treating pigmentary conditions and melanoma |
| 02/18/2010 | CA2734335A1 Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof |
| 02/18/2010 | CA2734179A1 Micro-rna-based compositions and methods for the diagnosis, prognosis and treatment of multiple myeloma |
| 02/18/2010 | CA2734147A1 Purine nucleoside phosphorylase as enzymatic activator of nucleoside prodrugs |
| 02/18/2010 | CA2734077A1 2-alkyl-6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-ib]-pyridazine derivatives, preparation thereof, and therapeutic application thereof |
| 02/18/2010 | CA2733963A1 Encapsulation of lipophilic or amphiphilic therapeutic agents in nano-emulsions |
| 02/18/2010 | CA2733941A1 Bicyclic triazole derivatives for the treatment of tumours |
| 02/18/2010 | CA2733749A1 Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
| 02/18/2010 | CA2733743A1 Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
| 02/18/2010 | CA2733726A1 Novel protease inhibitors |
| 02/18/2010 | CA2733642A1 Anti-il-12/il-23 antibodies |
| 02/18/2010 | CA2733636A1 The use of wnt5-a peptide derivates for the treatment of melanoma and gastric cancer |
| 02/18/2010 | CA2733445A1 Pyrrolo[4,3,2-de]quinolin-8-amine compounds and methods of their preparation and use |
| 02/18/2010 | CA2732922A1 2-amino pyrimidine compounds as potent hsp-90 inhibitors |
| 02/18/2010 | CA2732508A1 Multi-arm polymeric alkanoate conjugates |
| 02/18/2010 | CA2731108A1 Cmet inhibitors |
| 02/17/2010 | EP2154147A1 A truncated l1 protein of human papillomavirus 16 |
| 02/17/2010 | EP2154145A2 Dimerized peptide |
| 02/17/2010 | EP2153847A1 Gene sensitive to bone/joint disease and use thereof |
| 02/17/2010 | EP2153846A1 Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immonostimulatory molecule |
| 02/17/2010 | EP2153845A1 Endoglin peptides, vaccines and methods for preparing the same |
| 02/17/2010 | EP2153843A1 Compositions and methods for the diagnosis and treatment of tumor |
| 02/17/2010 | EP2153820A1 Liposome and method for producing liposome |
| 02/17/2010 | EP2152754A2 Monoclonal antibodies against claudin-18 for treatment of cancer |
| 02/17/2010 | EP2152753A1 Antibodies against ramp3 |
| 02/17/2010 | EP2152740A1 Products for altering il-33 activity and methods therefor |
| 02/17/2010 | EP2152737A2 Methods of treating, diagnosing and detecting fgf21-associated disorders |
| 02/17/2010 | EP2152714A1 Spiroindolinone derivatives |
| 02/17/2010 | EP2152705A1 9- (pyrazol- 3 -yl) - 9h- purine-2 -amine and 3- (pyraz0l-3-yl) -3h-imidaz0 [4, 5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
| 02/17/2010 | EP2152702A1 Amino-thiazolyl- pyrimidine derivatives and their use for the treatment of cancer |
| 02/17/2010 | EP2152701A1 Phenyl amino pyrimidine compounds and uses thereof |
| 02/17/2010 | EP2152700A1 Csf-1r inhibitors, compositions, and methods of use |
| 02/17/2010 | EP2152696A1 Aminopyrimidines useful as kinase inhibitors |
| 02/17/2010 | EP2152693A1 2-morpholin-4-yl-pyrimidines as pi3k inhibitors |
| 02/17/2010 | EP2152688A1 Compounds and compositions as c-kit and pdgfr kinase inhibitors |
| 02/17/2010 | EP2152686A1 Hydroxy sulfonate of quinone compounds and their uses |
| 02/17/2010 | EP2152676A1 "triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives" |
| 02/17/2010 | EP2152672A1 Novel sulphoximine-substituted quinazoline and quinazoline derivatives as kinase inhibitors |
| 02/17/2010 | EP2152370A1 Aryl ether pyridazinone derivatives |
| 02/17/2010 | EP2152369A2 Use of fluoride-containing compounds for diagnostic purposes with the help of imaging processes |
| 02/17/2010 | EP2152307A1 Inhibition of tumor metastasis by anti neuropilin 2 antibodies |
| 02/17/2010 | EP2152295A1 Klotho protein and related compounds for the treatment and diagnosis of cancer |
| 02/17/2010 | EP2152292A1 Angiogenesis inhibitor comprising meteorin as an active ingredient |
| 02/17/2010 | EP2152283A1 Water soluble opuntia extracts for the inhibition of alpha-1-adrenergic receptors |
| 02/17/2010 | EP2152282A1 Method and preparation of herbal extract of calotropis gigantea for cancer treatment |
| 02/17/2010 | EP2152273A2 Polymerase inhibitors and the use thereof for the treatment of tumors |